Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

14.52 -1.08 (-6.92%)
Official Closing Price Updated: 7:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
MarketBeat Week in Review – 02/23 - 02/27 ↗
Sometimes the best offense is a good defense. That’s what investors seem to be feeling. Technology stocks continue to be under pressure, and that money is flowing into traditionally defensive assets... 
Via MarketBeat
News headline image
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key... 
Via StockStory
Topics Economy Government Stocks
News headline image
Law Offices of Howard G. Smith Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Hims & Hers Health Inc (NYSE:HIMS) Stock Falls on Weak Q1 2026 Revenue Guidance Despite Q4 Earnings Beat ↗
Via Chartmill
HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? ↗
Via Stocktwits
News headline image
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back? ↗
The company is looking toward international markets to boost its growth. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗
Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising. 
Via The Motley Fool
News headline image
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026
As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗
How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think. 
Via The Motley Fool
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
HIMS Stock Plummets After Wall Street Downgrade, Price Target Cuts Following 'Disappointing' Q4 Report ↗
HIMS stock is currently trading at levels last seen in September 2024 and has fallen over 50% year-to-date. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Hims & Hers Health (HIMS): Decoding the Q4 Earnings Beat vs. the SEC GLP-1 Investigation
As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4... 
Via Finterra
Topics Earnings Economy Initial Public Offering
News headline image
Nasdaq, S&P 500 Futures Steady After AI Fears Roil Tech: Why IBM, NVDA, NFLX, HIMS, PFE Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on SPY and QQQ remained ‘bearish’ on Stocktwits. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
HIMS Stock Slumps Nearly 10% After-Hours: How CEO Dudum Plans To Offset GLP-1 Risk ↗
The company reiterated its longer-term targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. 
Via Stocktwits
Topics Earnings
News headline image
Hims & Hers (HIMS) Earnings Call Transcript ↗
Hims & Hers (HIMS) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million ↗
Hims & Hers Health Inc (NYSE:HIMS) reports financial results for the fourth quarter after the market close on Monday. 
Via Benzinga
News headline image
Hims & Hers Health’s (NYSE:HIMS) Q4 CY2025 Earnings Results: Revenue In Line With Expectations
Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 28.4% year on year to $617.8 million. On the other hand, next quarter’s revenue... 
Via StockStory
News headline image
Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
From Hims & Hers
Via Business Wire
News headline image
High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026
As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the... 
Via Finterra
Topics Artificial Intelligence Intellectual Property Lawsuit
News headline image
HIMS Stock Short Interest At Record Levels Ahead Of Q4 Earnings: What Are Bears Betting Against? ↗
Short interest climbed from about 18.5% on Jan.1 to 33.7% by Monday. 
Via Stocktwits
News headline image
What To Expect From Hims & Hers Health’s (HIMS) Q4 Earnings
Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market close. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
News headline image
Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside ↗
Via MarketBeat
News headline image
Hims & Hers HUGE Acquisition News! ↗
Hims & Hers is acquiring Eucalyptus and spreading its wings internationally. 
Via The Motley Fool
News headline image
Hims & Hers Health Makes Australia, Japan Foray With $1.15 Billion Eucalyptus Acquisition ↗
Hims & Hers Health, Inc. (HIMS) announced on Thursday that it has signed a definitive agreement to acquire Eucalyptus in a deal valued at up to $1.15 billion. 
Via Stocktwits
News headline image
Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform
From Hims & Hers
Via Business Wire
News headline image
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
2 Profitable Stocks on Our Watchlist and 1 We Ignore
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗
The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease. 
Via Stocktwits
News headline image
The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS)
Today is February 10, 2026. The telehealth landscape stands at a historic inflection point, and no company better embodies this volatility than Hims & Hers Health, Inc. (NYSE: HIMS). After a meteoric... 
Via Finterra
Topics Artificial Intelligence Intellectual Property Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.